Lentivectors encoding immunosuppressive proteins genetically engineer pancreatic β-cells to correct diabetes in allogeneic mice

Gene Therapy

Volumn 16, Issue 3, 2009, Pages 340-348

  Kojaoghlanian, T ^a   Joseph, A ^a   Follenzi, A ^a   Zheng, J H ^a   Leiser, M ^a   Fleischer, N ^a   Horwitz, M S ^a   DiLorenzo, T P ^a   Goldstein, H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GLYCOPROTEIN GP 18K; IMMUNOSUPPRESSIVE AGENT; LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECEPTOR INTERNALIZATION AND DEGRADATION COMPLEX ALPHA SUBUNIT; RECEPTOR INTERNALIZATION AND DEGRADATION COMPLEX BETA SUBUNIT; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EFFECTOR CELL; GENETIC ENGINEERING; GRAFT REJECTION; HYPERGLYCEMIA; MOUSE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME;

ADENOVIRUS E3 PROTEINS; ADENOVIRUS EARLY PROTEINS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GENETIC ENGINEERING; GENETIC VECTORS; GRAFT REJECTION; IMMUNE TOLERANCE; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; LENTIVIRUS; MICE; MICE, INBRED C3H; MICE, INBRED STRAINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSDUCTION, GENETIC;

MUS;

EID: 62549098121     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.172     Document Type: Article

References (43)

1. Edge AS. Current applications of cellular xenografts. Transplant Proc 2000; 32: 1169-1171.
2. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM et al Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069.
3. Balamurugan AN, Bottino R, Giannoukakis N, Smetanka C. Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes. Pancreas 2006; 32: 231-243.
4. Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by β cell regeneration. J Clin Invest 2007; 117: 2553-2561.
5. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-1330.
6. Horwitz MS. Function of adenovirus E3 proteins and their interactions with immunoregulatory cell proteins. J Gene Med 2004; 6 (Suppl 1): S172-S183.
7. Benedict CA, Norris PS, Prigozy TI, Bodmer JL, Mahr JA, Garnett CT et al. Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem 2001; 276: 3270-3278.
8. Gooding LR, Ranheim TS, Tollefson AE, Aquino L, Duerksen-Hughes P, Horton TM et al. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J Virol 1991; 65: 4114-4123.
9. Shisler J, Yang C, Walter B, Ware CF, Gooding LR. The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol 1997; 71: 8299-8306.
10. Friedman JM, Horwitz MS. Inhibition of tumor necrosis factor alpha-induced NF-κB activation by the adenovirus E3-10.4/14.5K complex. J Virol 2002; 76: 5515-5521.
11. Delgado-Lopez F, Horwitz MS. Adenovirus RIDαβ complex inhibits lipopolysaccharide signaling without altering TLR4 cell surface expression. J Virol 2006; 80: 6378-6386.
12. Burgert HG, Maryanski JL, Kvist S. 'E3/19K' protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens. Proc Natl Acad Sci USA 1987; 84: 1356-1360.
13. Beilke J, Johnson Z, Kuhl N, Gill RG. A major role for host MHC class I antigen presentation for promoting islet allograft survival. Transplant Proc 2004; 36: 1173-1174.
14. Sigrist S, Ebel N, Langlois A, Bosco D, Toso C, Kleiss C et al. Role of chemokine signaling pathways in pancreatic islet rejection during allo- and xenotransplantation. Transplant Proc 2005; 37 3516-3518.
15. Eizirik DL, Mandrup-Poulsen T. A choice of death - the signal transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133.
16. Yang Y, Santamaria P. Dissecting autoimmune diabetes through genetic manipulation of non-obese diabetic mice. Diabetologia 2003; 46 1447-1464.
17. Efrat S, Fejer G, Brownlee M, Horwitz MS. Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes. Proc Natl Acad Sci USA 1995; 92: 6947-6951.
18. Efrat S, Serreze D, Svetlanov A, Post CM, Johnson EA, Herold K et al Adenovirus early region 3 (E3) immunomodulatory genes decrease the incidence of autoimmune diabetes in NOD mice. Diabetes 2001; 50 980-984.
19. Pierce MA, Chapman HD, Post CM, Svetlanov A, Efrat S, Horwitz M et al Adenovirus early region 3 antiapoptotic 10.4K, 14.5K, and 14.7K genes decrease the incidence of autoimmune diabetes in NOD mice. Diabetes 2003; 52: 1119-1127.
20. von Herrath MG, Efrat S, Oldstone MB, Horwitz MS. Expression of adenoviral E3 transgenes in b cells prevents autoimmune diabetes. Proc Natl Acad Sci USA 1997; 94: 9808-9813.
21. Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X et al Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103: 17372-17377.
22. Efrat S, Fusco-DeMane D, Lemberg H, al Emran O, Wang X. Conditional transformation of a pancreatic β-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci USA 1995; 92: 3576-3580.
23. Fleischer N, Chen C, Surana M, Leiser M, Rossetti L, Pralong W et al Functional analysis of a conditionally transformed pancreatic β-cell line. Diabetes 1998; 47: 1419-1425.
24. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF et al. Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22: 589-594.
25. Follenzi A, Naldini L. Generation of HIV-1 derived lentiviral vectors. Methods Enzymol 2002; 346: 454-465.
26. Petrovsky N, Silva D, Socha L, Slattery R, Charlton B. The role of Fas ligand in beta cell destruction in autoimmune diabetes of NOD mice. Ann N Y Acad Sci 2002; 958: 204-208.
27. Dupraz P, Rinsch C, Pralong WF, Rolland E, Zufferey R, Trono D et al Lentivirus-mediated Bcl-2 expression in βTC-tet cells improves resistance to hypoxia and cytokine-induced apoptosis while preserving in vitro and in vivo control of insulin secretion. Gene Therapy 1999; 6: 1160-1169.
28. Gallichan WS, Kafri T, Krahl T, Verma IM, Sarvetnick N. Lentivirus-mediated transduction of islet grafts with interleukin 4 results in sustained gene expression and protection from insulitis. Hum Gene Ther 1998; 9: 2717-2726.
29. Grey ST, Arvelo MB, Hasenkamp W, Bach FH, Ferran C. A20 inhibits cytokine-induced apoptosis and nuclear factor κB-dependent gene activation in islets. J ExpMed 1999; 190: 1135-1146.
30. Machen J, Bertera S, Chang Y, Bottino R, Balamurugan AN, Robbins PD et al. Prolongation of islet allograft survival following ex vivo transduction with adenovirus encoding a soluble type 1 TNF receptor-Ig fusion decoy. Gene Therapy 2004; 11: 1506-1514.
31. Papeta N, Chen T, Vianello F, Gererty L, Malik A, Mok YT et al. Long-term survival of transplanted allogeneic cells engineered to express a T cell chemorepellent. Transplantation 2007; 83: 174-183.
32. Rabinovitch A, Suarez-Pinzon W, Strynadka K, Ju Q, Edelstein D, BrownleeM et al. Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects b-cells from cytokine-induced destruction. Diabetes 1999; 48: 1223-1229.
33. Lunsford KE, Gao D, Eiring AM, Wang Y, Frankel WL, Bumgardner GL. Evidence for tissue-directed immune responses: Analysis of CD4- and CD8-dependent alloimmunity. Transplantation 2004; 78: 1125-1133.
34. Elsing A, Burgert HG. The adenovirus E3/10.4K-14.5K proteins down-modulate the apoptosis receptor Fas/Apo-1 by inducing its internalization. Proc Natl Acad Sci USA 1998; 95: 10072-10077.
35. Kobinger GP, Deng S, Louboutin JP, Vatamaniuk M, Matschinsky F, Markmann JF et al. Transduction of human islets with pseudotyped lentiviral vectors. Hum Gene Ther 2004; 15: 211-219.
36. Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007; 19: 309-314.
37. Ilan Y, Droguett G, Chowdhury NR, Li Y, Sengupta K, Thummala NR et al Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997; 94: 2587-2592.
38. Ravelingien A. Xenotransplantation: The ethical and legal concerns. Xenotransplantation 2007; 14: 653-654.
39. Efrat S. Beta-cell replacement for insulin-dependent diabetes mellitus. Adv Drug Deliv Rev 2008; 60: 114-123.
40. Sapir T, Shternhall K, Meivar-Levy I, Blumenfeld T, Cohen H, Skutelsky E et al. Cell-replacement therapy for diabetes: Generating functional insulin-producing tissue from adult human liver cells. Proc Natl Acad Sci USA 2005; 102: 7964-7969.
41. Zalzman M, Gupta S, Giri RK, Berkovich I, Sappal BS, Karnieli O et al Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proc Natl Acad Sci USA 2003; 100: 7253-7258.
42. Joseph A, Zheng JH, Follenzi A, Dilorenzo T, Sango K, Hyman J et al Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. J Virol 2008; 82: 3078-3089.
43. D'Ambra R, Surana M, Efrat S, Starr RG, Fleischer N. Regulation of insulin secretion from b-cell lines derived from transgenic mice insulinomas resembles that of normal β cells. Endocrinology 1990; 126: 2815-2822.